[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647377":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":22,"centralContacts":22,"locations":22,"responsibleParty":32,"collaborators":22,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":42,"eligibilityCriteria":43,"healthyVolunteers":38,"sex":44,"minAge":45,"maxAge":46,"enrollmentInfo":47,"targetDuration":22,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":22,"overallStatus":56,"whyStopped":22,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":22},{"fullName":5,"class":6},"Tianjin First Central Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"nimotuzumab group","EXPERIMENTAL","treatment group",[13,14,15],"Drug: nimotuzumab","Drug: Temozolomide","Radiation: Radiotherapy",[17,23,27],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"DRUG","nimotuzumab","Nimotuzumab 200 mg will be administered via intravenous infusion once weekly for 6 weeks, followed by 200 mg via intravenous infusion once every 4 weeks for a total of 6 doses.",[9],null,{"type":18,"name":24,"description":25,"armGroupLabels":26,"otherNames":22},"Temozolomide","Temozolomide will be administered orally at a dose of 150-200 mg\u002Fm²\u002Fday for 5 consecutive days. Each cycle lasts 28 days, for a total of 6 cycles.",[9],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":22},"RADIATION","Radiotherapy","PTV：60Gy\u002F2Gy\u002F30f，6weeks",[9],{"type":33,"investigatorFullName":34,"investigatorTitle":35,"investigatorAffiliation":5,"oldNameTitle":22,"oldOrganization":22},"PRINCIPAL_INVESTIGATOR","Wei Jiang","Professor","100647377","phase-2-nimotuzumab-combined-with-the-stupp-regimen-for-postoperative-residual-glioblastoma-100647377",false,"NCT07707973","Nimotuzumab Combined With the Stupp Regimen for Postoperative Residual Glioblastoma","A Single-arm, Phase II Study of Nimotuzumab Combined With the Stupp Regimen for Postoperative Residual Glioblastoma","Nimotuzumab","Inclusion Criteria:\n\n* 1）Aged 18 to 75 years.\n* 2）Newly diagnosed glioblastoma consistent with the World Health Organization (WHO) Classification of Tumours of the Central Nervous System, 5th edition.\n* 3）Epidermal growth factor receptor (EGFR)-positive status confirmed by immunohistochemistry (defined as brown-yellow staining in \\>10% of tumor cells).\n* 4）Partial surgical resection with radiographically measurable residual tumor.\n* 5）Karnofsky Performance Status (KPS) score ≥ 50% (with KPS decline attributable to the tumor).\n* 6）Adequate renal function, defined as serum creatinine ≤ 1.5 times the upper limit of normal (ULN) or creatinine clearance \\> 60 mL\u002Fmin.\n* 7）Adequate hepatic function, defined as total bilirubin ≤ 1.5 times the ULN and serum transaminases ≤ 3 times the ULN.\n* 8）Adequate hematologic function, defined as a white blood cell count ≥ 3,000\u002FμL or an absolute neutrophil count (ANC) ≥ 1,500\u002FμL, platelet count ≥ 100,000\u002FμL, and hemoglobin ≥ 10 g\u002FdL.\n* 9）An interval of 2 to 6 weeks between surgical resection and the initiation of radiotherapy (RT).\n\nExclusion Criteria:\n\n* 1）EGFR-negative status.\n* 2）Prior treatment with chemotherapy, anti-EGFR therapy, or radiotherapy; or a history of other malignancies within the past 5 years.\n* 3）Presence of severe comorbidities or active infections, or persistent vomiting that may interfere with the oral administration of temozolomide (TMZ).","ALL","18 Years","75 Years",{"count":48,"type":49},50,"ESTIMATED","INTERVENTIONAL",[52],"PHASE2","This is a prospective, single-arm study. The study population consists of adult patients with a confirmed diagnosis of EGFR-positive high-grade glioma who have radiographic residual tumor following surgical resection. Participants will receive nimotuzumab in combination with the standard Stupp regimen after glioma surgery.",[55],"Glioma, Malignant","NOT_YET_RECRUITING","2026-07-12",{"date":59,"type":60},"2026-07-16","ACTUAL",{"date":62,"type":49},"2026-07-03",{"date":64,"type":49},"2029-06-03",{"name":5,"class":6}]